Uncategorized

Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use

Published

on

The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the product, according to William Blair.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version